CoChat
Sign Up
Cited by 40Cardiac Health and Mental HealthTreatment of Major DepressionMental Health Treatment and Access

Antidepressant use and risk of coronary heart disease: meta‐analysis of observational studies

Open access
Oh, Seung‐Won, Kim, Joonseok, Myung, Seung‐Kwon, Hwang, Seung‐Sik, Yoon, Dae‐Hyun·2014·British Journal of Clinical Pharmacology
DOI 10.1111/bcp.12383PMC PMC4239967
Open this paper in CoChat — free accountOpen PDF

Abstract

Aims: Our goal was to evaluate the association between antidepressant use and the risk of coronary heart disease (CHD) among subjects with no history of coronary heart disease. Methods: A search of M edline, EMBASE, PsycINFO and the C ochrane L ibrary was performed in J anuary 2013. Two authors independently reviewed and selected eligible observational studies, based on predetermined selection criteria. Pooled relative risks (RR s) with confidence intervals (CIs) were calculated using random‐effects or fixed‐effects models. Results: Sixteen observational studies (seven case–control studies and nine cohort studies) were included in the final analysis. There was no association between selective serotonin reuptake inhibitor use and the risk of CHD overall [odds ratio (OR), 0.93; 95% CI, 0.65–1.33] or in subgroup meta‐analysis of case–control studies (OR, 0.91; 95% CI, 0.60–1.37) and cohort studies (RR, 0.96; 95% CI, 0.59–1.55). The use of tricyclic antidepressant was associated with an increased risk of CHD overall (OR, 1.51; 95% CI, 1.07–2.12), but it was observed only in case–control studies (OR, 1.56; 95% CI, 1.24–1.96) and low‐quality studies (OR, 1.49; 95% CI, 1.20–1.85) in the subgroup meta‐analyses. Conclusions: This meta‐analysis of observational studies in subjects with no history of CHD suggests that neither selective serotonin reuptake inhibitor nor tricyclic antidepressant use is associated with an increased risk of CHD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bcp.12383

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 53

  1. Reid S, Barbui C. Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants. BMJ 2010; 340: c1468.
  2. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med 2000; 108: 2-8.
  3. Lapane KL, Zierler S, Lasater TM, Barbour MM, Carleton R, Hume AL. Is the use of psychotropic drugs associated with increased risk of ischemic heart disease? Epidemiology 1995; 6: 376-81.
  4. Penttinen J, Valonen P. Use of psychotropic drugs and risk of myocardial infarction: a case-control study in Finnish farmers. Int J Epidemiol 1996; 25: 760-2.
  5. Rosenberg LB, Whang W, Shimbo D, Shah A, Shapiro PA, Davidson KW. Exposure to tricyclic antidepressants is associated with an increased risk of incident CHD events in a population-based study. Int J Cardiol 2010; 145: 124-5.
  6. Hippisley-Cox J, Pringle M, Hammersley V, Crown N, Wynn A, Meal A, Coupland C. Antidepressants as risk factor for ischaemic heart disease: case-control study in primary care. BMJ 2001; 323: 666-9.
  7. Tata LJ, West J, Smith C, Farrington P, Card T, Smeeth L, Hubbard R. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart 2005; 91: 465-71.
  8. Blanchette CM, Simoni-Wastila L, Zuckerman IH, Stuart B. A secondary analysis of a duration response association between selective serotonin reuptake inhibitor use and the risk of acute myocardial infarction in the aging population. Ann Epidemiol 2008; 18: 316-21.
  9. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001; 104: 1894-8.
  10. Scherrer JF, Garfield LD, Lustman PJ, Hauptman PJ, Chrusciel T, Zeringue A, Carney RM, Freedland KE, Bucholz KK, Owen R, Newcomer JW, True WR. Antidepressant drug compliance: reduced risk of MI and mortality in depressed patients. Am J Med 2011; 124: 318-24.
  11. Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Eaton WW. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation 1996; 94: 3123-9.
  12. Hippisley-Cox J, Fielding K, Pringle M. Depression as a risk factor for ischaemic heart disease in men: population based case-control study. BMJ 1998; 316: 1714-9.
  13. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003; 108: 32-6.
  14. Monster TB, Johnsen SP, Olsen ML, McLaughlin JK, Sorensen HT. Antidepressants and risk of first-time hospitalization for myocardial infarction: a population-based case-control study. Am J Med 2004; 117: 732-7.
  15. Smoller JW, Allison M, Cochrane BB, Curb JD, Perlis RH, Robinson JG, Rosal MC, Wenger NK, Wassertheil-Smoller S. Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women's Health Initiative study. Arch Intern Med 2009; 169: 2128-39.
  16. Whang W, Kubzansky LD, Kawachi I, Rexrode KM, Kroenke CH, Glynn RJ, Garan H, Albert CM. Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses' Health Study. J Am Coll Cardiol 2009; 53: 950-8.
  17. Hamer M, David Batty G, Seldenrijk A, Kivimaki M. Antidepressant medication use and future risk of cardiovascular disease: the Scottish Health Survey. Eur Heart J 2011; 32: 437-42.
  18. Kimmel SE, Schelleman H, Berlin JA, Oslin DW, Weinstein RB, Kinman JL, Sauer WH, Lewis JD. The effect of selective serotonin re-uptake inhibitors on the risk of myocardial infarction in a cohort of patients with depression. Br J Clin Pharmacol 2011; 72: 514-7.
  19. Pizzi C, Rutjes AW, Costa GM, Fontana F, Mezzetti A, Manzoli L. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol 2011; 107: 972-9.
  20. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 1955; 19: 251-3.
  21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
  22. Martinez C, Assimes TL, Mines D, Dell'aniello S, Suissa S. Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study. BMJ 2010; 340: c249.
  23. Salaycik KJ, Kelly-Hayes M, Beiser A, Nguyen AH, Brady SM, Kase CS, Wolf PA. Depressive symptoms and risk of stroke: the Framingham Study. Stroke 2007; 38: 16-21.
  24. Surtees PG, Wainwright NW, Luben RN, Wareham NJ, Bingham SA, Khaw KT. Depression and ischemic heart disease mortality: evidence from the EPIC-Norfolk United Kingdom prospective cohort study. Am J Psychiatry 2008; 165: 515-23.
  25. Xue F, Strombom I, Turnbull B, Zhu S, Seeger JD. Cardiovascular events in duloxetine users compared to other depressed and non-depressed subjects. Pharmacoepidemiol Drug Saf 2009; 18: S96.
  26. Pan A, Okereke OI, Sun Q, Logroscino G, Manson JE, Willett WC, Ascherio A, Hu FB, Rexrode KM. Depression and incident stroke in women. Stroke 2011; 42: 2770-5.
  27. Xue F, Strombom I, Turnbull B, Zhu S, Seeger J. Treatment with duloxetine in adults and the incidence of cardiovascular events. J Clin Psychopharmacol 2012; 32: 23-30.
  28. Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, Kaufmann PG, Shuster J, Mellman T, Blumenthal JA, Krishnan R, Jaffe AS, ENRICHD Investigators. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005; 62: 792-8.
  29. Chen Y, Guo JJ, Patel NC. Hemorrhagic stroke associated with antidepressant use in patients with depression: does degree of serotonin reuptake inhibition matter? Pharmacoepidemiol Drug Saf 2009; 18: 196-202.
  30. Winterstein AG, Gerhard T, Kubilis P, Saidi A, Linden S, Crystal S, Zito J, Shuster JJ, Olfson M. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. BMJ 2012; 345: e4627.
  31. Caso V, Santalucia P, Pezzella FR. Depression and stroke risk. Womens Health (Lond Engl) 2012; 8: 35-7.
  32. Abas M, Hotopf M, Prince M. Depression and mortality in a high-risk population. 11-Year follow-up of the Medical Research Council Elderly Hypertension Trial. Br J Psychiatry 2002; 181: 123-8.
  33. Ray JG, Mamdani MM, Yeo EL. Antipsychotic and antidepressant drug use in the elderly and the risk of venous thromboembolism. Thromb Haemost 2002; 88: 205-9.
  34. Jick SS, Li L. Antidepressant drug use and risk of venous thromboembolism. Pharmacotherapy 2008; 28: 144-50.
  35. Mast ST, Gersing KR, Anstrom KJ, Krishnan KR, Califf RM, Jollis JG. Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation. Am J Cardiol 2001; 87: 989-93.
  36. Seifert CL, Poppert H, Sander D, Feurer R, Etgen T, Ander KH, Pürner K, Brönner M, Sepp D, Kehl V, Förstl H, Bickel H. Depressive symptoms and the risk of ischemic stroke in the elderly -influence of age and sex. PLoS One 2012; 7: e50803.
  37. Majed B, Arveiler D, Bingham A, Ferrieres J, Ruidavets JB, Montaye M, Appleton K, Haas B, Kee F, Amouyel P, Ducimetiere P, Empana JP, PRIME Study Group. Depressive symptoms, a time-dependent risk factor for coronary heart disease and stroke in middle-aged men: the PRIME Study. Stroke 2012; 43: 1761-7.
  38. Castro VM, Gallagher PJ, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis RH. Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants. BMJ Open 2012; 2: e000544.
  39. Li CT, Bai YM, Tu PC, Lee YC, Huang YL, Chen TJ, Chang WH, Su TP. Major depressive disorder and stroke risks: a 9-year follow-up population-based, matched cohort study. PLoS One 2012; 7: e46818.
  40. D'Cruz S, Sachdev A, Tiwari P. Adverse drug reactions & their risk factors among Indian ambulatory elderly patients. Indian J Med Res 2012; 136: 404-10.
  41. Hung CC, Lin CH, Lan TH, Chan CH. The association of selective serotonin reuptake inhibitors use and stroke in geriatric population. Am J Geriatr Psychiatry 2013; 21: 811-5.
  42. Nabi H, Kivimaki M, Suominen S, Koskenvuo M, Singh-Manoux A, Vahtera J. Does depression predict coronary heart disease and cerebrovascular disease equally well? The Health and Social Support Prospective Cohort Study. Int J Epidemiol 2010; 39: 1016-24.
  43. Schlienger RG, Meier CR. Effect of selective serotonin reuptake inhibitors on platelet activation: can they prevent acute myocardial infarction? Am J Cardiovasc Drugs 2003; 3: 149-62.
  44. Stollerman GH, Bisno AL. Antidepressants and myocardial infarction. Hosp Pract 2000; 35: 26-141.
  45. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, Krishnan KR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM, Barton D, McLvor M. Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288: 701-9.
  46. Lespérance F, Frasure-Smith N, Koszycki D, Laliberté MA, van Zyl LT, Baker B, Swenson JR, Ghatavi K, Abramson BL, Dorian P, Guertin MC, CREATE Investigators. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007; 297: 367-79.
  47. Pizzi C, Mancini S, Angeloni L, Fontana F, Manzoli L, Costa GM. Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clin Pharmacol Ther 2009; 86: 527-32.
  48. Pizzi C, Manzoli L, Mancini S, Bedetti G, Fontana F, Costa GM. Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors. Atherosclerosis 2010; 212: 292-8.
  49. Penninx BW, Beekman AT, Honig A, Deeg DJ, Schoevers RA, van Eijk JT, van Tilburg W. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 2001; 58: 221-7.
  50. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998; 55: 580-92.
  51. Zellweger MJ, Osterwalder RH, Langewitz W, Pfisterer ME. Coronary artery disease and depression. Eur Heart J 2004; 25: 3-9.
  52. O'Connor CM, Jiang W, Kuchibhatla M, Mehta RH, Clary GL, Cuffe MS, Christopher EJ, Alexander JD, Califf RM, Krishnan RR. Antidepressant use, depression, and survival in patients with heart failure. Arch Intern Med 2008; 168: 2232-7.
  53. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet 1999; 353: 89-92.

Cited by

Sorted by citations

Authors
Oh, S., Kim, J., Myung, S., Hwang, S., & Yoon, D.
Affiliations
  • Seoul National University Hospital (KR)
  • Department of Medicine Michigan State University East Lansing MI 48824 USA
  • National Cancer Center (KR)
  • Inha University (KR)
Corresponding author
Myung, Seung‐Kwon
ORCID
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2014-09-19
Volume
78
Issue
4
Pages
727-737
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
DOI
10.1111/bcp.12383
PMC
PMC4239967
OpenAlex
W1864827731
Cited by
40
References
3
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 1 · 2022: 5 · 2021: 5 · 2020: 6 · 2019: 4 · 2018: 4 · 2017: 2 · 2016: 6 · 2015: 3
FWCI
0.59
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • British Journal of Clinical Pharmacology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (UL1TR001425)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Social Sciences › Psychology › Social Psychology › Mental Health Treatment and Access
Keywords
antidepressants, coronary artery disease, selective serotonin reuptake inhibitors, tricyclic antidepressants, cardiovascular risk, drug safety, observational studies
MeSH terms
Antidepressive Agents, Antidepressive Agents, Tricyclic, Coronary Disease, Female, Humans, Male, Risk, Selective Serotonin Reuptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review